214 related articles for article (PubMed ID: 2350535)
1. A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients.
Patsalos PN
Br J Clin Pharmacol; 1990 May; 29(5):574-7. PubMed ID: 2350535
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and tolerability of chewable carbamazepine compared to conventional carbamazepine in patients with epilepsy.
Patsalos PN; Russell-Jones D; Finnerty G; Sander JW; Shorvon SD
Epilepsy Res; 1990 Apr; 5(3):235-9. PubMed ID: 2384079
[TBL] [Abstract][Full Text] [Related]
3. The pharmacology of chewable versus regular carbamazepine in chronically treated children with epilepsy.
Camfield P; Hwang P; Camfield C; Fraser A; Soldin S; al-Quadah AK
Can J Neurol Sci; 1992 May; 19(2):204-7. PubMed ID: 1623447
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetic study of chewable and conventional carbamazepine in children.
Cornaggia C; Gianetti S; Battino D; Granata T; Romeo A; Viani F; Limido G
Epilepsia; 1993; 34(1):158-60. PubMed ID: 8422850
[TBL] [Abstract][Full Text] [Related]
5. Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients.
McKee PJ; Blacklaw J; Carswell A; Gillham RA; Brodie MJ
Br J Clin Pharmacol; 1993 Sep; 36(3):257-61. PubMed ID: 9114913
[TBL] [Abstract][Full Text] [Related]
6. Multiple-dose pharmacokinetic study with a slow-release carbamazepine preparation.
Reunanen M; Heinonen E; Anttila M; Järvensivu P; Lehto H; Hokkanen E
Epilepsy Res; 1990 Jul; 6(2):126-33. PubMed ID: 2387286
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and cognitive effects of carbamazepine formulations with different dissolution rates.
Aldenkamp AP; Rentmeester T; Hulsman J; Majoie M; Doelman J; Diepman L; Schellekens A; Franken M; Olling M
Eur J Clin Pharmacol; 1998 Apr; 54(2):185-92. PubMed ID: 9626926
[TBL] [Abstract][Full Text] [Related]
8. Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients.
McKee PJ; Blacklaw J; Butler E; Gillham RA; Brodie MJ
Br J Clin Pharmacol; 1991 Jul; 32(1):99-104. PubMed ID: 1888646
[TBL] [Abstract][Full Text] [Related]
9. A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects.
Larkin JG; McLellan A; Munday A; Sutherland M; Butler E; Brodie MJ
Br J Clin Pharmacol; 1989 Mar; 27(3):313-22. PubMed ID: 2655682
[TBL] [Abstract][Full Text] [Related]
10. Comparative bioavailability of carbamazepine from two slow-release preparations.
Reunanen M; Heinonen EH; Nyman L; Anttila M
Epilepsy Res; 1992 Mar; 11(1):61-6. PubMed ID: 1563339
[TBL] [Abstract][Full Text] [Related]
11. Fluctuations in salivary carbamazepine and carbamazepine-10,11-epoxide concentrations during the day in epileptic children.
Paxton JW; Aman MG; Werry JS
Epilepsia; 1983 Dec; 24(6):716-24. PubMed ID: 6641647
[TBL] [Abstract][Full Text] [Related]
12. A comparative bioavailability study of carbamazepine tablets and a chewable tablet formulation.
Maas B; Garnett WR; Pellock JM; Comstock TJ
Ther Drug Monit; 1987; 9(1):28-33. PubMed ID: 3576660
[TBL] [Abstract][Full Text] [Related]
13. Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation.
Konsil J; Dechasathian S; Mason DH; Stevens RE
J Pharm Pharm Sci; 2002; 5(2):169-75. PubMed ID: 12207869
[TBL] [Abstract][Full Text] [Related]
14. Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg.
Revankar SN; Bhatt AD; Desai ND; Bolar HV; Sane SP; Tipnis HP
J Assoc Physicians India; 1999 Sep; 47(9):886-9. PubMed ID: 10778658
[TBL] [Abstract][Full Text] [Related]
15. Distribution of carbamazepine and its epoxide in blood compartments in adolescent and adult epileptic patients.
Bonneton J; Genton P; Mesdjian E
Biopharm Drug Dispos; 1992 Aug; 13(6):411-6. PubMed ID: 1391679
[TBL] [Abstract][Full Text] [Related]
16. Comparative bioavailability and steady state fluctuations of Tegretol commercial and carbamazepine OROS tablets in adult and pediatric epileptic patients.
Thakker KM; Mangat S; Garnett WR; Levy RH; Kochak GM
Biopharm Drug Dispos; 1992 Nov; 13(8):559-69. PubMed ID: 1421050
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of free carbamazepine in adult Omani epileptic patients.
Deleu D; Aarons L; Ahmed IA
Eur J Clin Pharmacol; 2001 Jun; 57(3):243-8. PubMed ID: 11497340
[TBL] [Abstract][Full Text] [Related]
18. Implications of metabolic parameters of carbamazepine in the therapeutic monitoring of Tunisian patients with epilepsy.
Chbili C; Hassine A; Ben Amor S; Nouira M; Ben Ammou S; Saguem S
Rev Neurol (Paris); 2016; 172(4-5):313-7. PubMed ID: 27062293
[TBL] [Abstract][Full Text] [Related]
19. Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects.
Bareggi SR; Tata MR; Guizzaro A; Pirola R; Parisi A; Monza CG
Int Clin Psychopharmacol; 1994; 9(1):9-16. PubMed ID: 8195585
[TBL] [Abstract][Full Text] [Related]
20. The 10,11-epoxide-10,11-diol pathway of carbamazepine in early pregnancy in maternal serum, urine, and amniotic fluid: effect of dose, comedication, and relation to outcome of pregnancy.
Omtzigt JG; Los FJ; Meijer JW; Lindhout D
Ther Drug Monit; 1993 Feb; 15(1):1-10. PubMed ID: 8451773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
